2022
Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse events
2021
Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease
Lansky AJ, Kereiakes DJ, Baumbach A, Windecker S, Hussain Y, Pietras C, Dressler O, Issever O, Curtis M, Bertolet B, Zidar JP, Smits PC, Díaz V, McLaurin B, Hofma S, Cequier Á, Dib N, Benit E, Mathur A, Brogno D, Berland J, Wykrzykowska J, Piegari G, Brugaletta S, Saito S, Leon MB, Investigators O. Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease. Circulation 2021, 143: 2143-2154. PMID: 33820424, DOI: 10.1161/circulationaha.120.052482.Peer-Reviewed Original ResearchConceptsDurable polymer everolimus-eluting stentsDrug-eluting stentsTarget lesion revascularizationAntiproliferative drug deliveryChronic coronary syndromeVessel myocardial infarctionLesion revascularizationCoronary syndromeLesion failureMyocardial infarctionDrug-Eluting Stent ImplantationTarget vessel myocardial infarctionLong-term clinical outcomesDP-EES groupPrimary end pointTarget lesion failureSmooth muscle cell proliferationPercutaneous coronary interventionSingle-blind trialCoronary artery diseaseEverolimus-eluting stentsMuscle cell proliferationLong-term inflammatory responseDrug eluting stentsCardiovascular death
2014
Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial)
Goto K, Lansky AJ, Ng VG, Pietras C, Nargileci E, Mehran R, Parise H, Feit F, Ohman EM, White HD, Bertrand ME, Desmet W, Hamon M, Stone GW. Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial). The American Journal Of Cardiology 2014, 114: 1638-1645. PMID: 25312637, DOI: 10.1016/j.amjcard.2014.09.003.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedAnticoagulantsCoronary AngiographyCoronary Artery DiseaseFemaleHemorrhageHeparinHirudinsHumansMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPeptide FragmentsPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexPrognosisRecombinant ProteinsSeverity of Illness IndexTreatment OutcomeConceptsPercutaneous coronary interventionAcute coronary syndromeType C lesionsGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsC lesionsLesion complexityBivalirudin monotherapyComposite ischemiaCoronary syndromeCoronary interventionIschemic eventsMyocardial infarctionCardiology/American Heart Association classificationAdverse short-term prognosisAmerican Heart Association classificationAdverse ischemic eventsComposite ischemic eventsContemporary interventional therapyMajor bleeding complicationsMajor hemorrhagic complicationsShort-term prognosisAcute CatheterizationAntithrombotic regimensMajor bleeding
2008
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial
Lansky AJ, Tsuchiya Y, Brener M, Mehran R, Cristea E, Pietras C, Grines CL, Cox DA, Garcia E, Tcheng JE, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Leon MB, Moses J, Stone GW. Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: Results from the CADILLAC trial. Catheterization And Cardiovascular Interventions 2008, 72: 917-924. PMID: 19016469, DOI: 10.1002/ccd.21714.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinClopidogrelCoronary AngiographyDrug Therapy, CombinationEuropeFemaleHemorrhageHumansImmunoglobulin Fab FragmentsMaleMiddle AgedMulticenter Studies as TopicMyocardial InfarctionMyocardial IschemiaPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRetrospective StudiesRisk AssessmentStentsThrombosisTiclopidineTime FactorsTreatment OutcomeUnited StatesConceptsAcute myocardial infarctionPrimary stentingCADILLAC trialRecurrent ischemiaSevere bleedingMyocardial infarctionEfficacy of clopidogrelMore recurrent ischemiaTIMI 0/1 flowSimilar clinical outcomesTiclopidine treatmentAngiographic characteristicsClopidogrel useIndependent predictorsClinical outcomesMultivariable analysisRandomized trialsStent thrombosisStent implantationOperator's discretionClopidogrelStentingPatientsTiclopidineRelative safety
2006
Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials)
Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Müller R, Störger H, Hauptmann KE, Grube E. Effect of Everolimus-Eluting Stents in Different Vessel Sizes (from the Pooled FUTURE I and II Trials). The American Journal Of Cardiology 2006, 98: 464-469. PMID: 16893698, DOI: 10.1016/j.amjcard.2006.02.054.Peer-Reviewed Original ResearchMeSH KeywordsAgedBlood Vessel Prosthesis ImplantationCoated Materials, BiocompatibleCoronary AngiographyCoronary RestenosisCoronary VesselsEverolimusFemaleFollow-Up StudiesHumansImmunosuppressive AgentsMaleMiddle AgedProspective StudiesProsthesis DesignSirolimusStentsTreatment OutcomeUltrasonography, InterventionalConceptsBare metal stentsDe novo coronary lesionsNovo coronary lesionsCoronary lesionsNeointimal proliferationStent late lumen lossMid-term outcomesLate lumen lossEverolimus-Eluting StentsQuantitative coronary angiographyMinimum lumen areaVessel sizeII trialCoronary angiographyI trialIncomplete appositionLumen lossStent thrombosisAneurysm formationStent restenosisIntravascular ultrasoundMetal stentsReference diameterLumen areaPatients
2005
Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction
Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, Aymong ED, Stuckey TD, Garcia E, Tcheng JE, Mehran R, Negoita M, Fahy M, Cristea E, Turco M, Leon MB, Grines CL, Stone GW. Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction. Circulation 2005, 111: 1611-1618. PMID: 15811868, DOI: 10.1161/01.cir.0000160362.55803.40.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionPrimary stentingAddition of abciximabBody surface areaCADILLAC trialMyocardial infarctionRisk factorsFemale genderIschemic target vessel revascularizationLower body surface areaMajor adverse cardiac eventsOverall adverse outcomesTIMI grade 3Adverse cardiac eventsTarget vessel revascularizationClinical risk factorsComorbid risk factorsInterventional treatment strategiesImportant independent determinantHigh mortality rateMACE ratePrimary angioplastyCardiac eventsSymptom onsetIndependent predictors